Skip to main content

Advances in Photodynamic Therapy Assisted by Electroporation

Buy Article:

$68.00 + tax (Refund Policy)

Low invasive therapies of cancer are directed toward the methods that target selectively on carcinoma cells. Photodynamic therapy (PDT) is a therapeutic modality in which combination of a photosensitizer, light, and oxygen renders reactive oxygen species (ROS) which cause damage to a tumor tissue. Each of these factors is not toxic in itself and the effect of therapy results from high uptake of a photosensitizer by carcinoma cells and directed tumor irradiation by light. Realization of the therapy depends on efficient transport of the photosensitizer across the membrane and intracellular accumulation of the drug. Depending on the treatment conditions and the uptake mechanism, sensitizers can potentially reach different intracellular concentrations and different cellular effects can be triggered. Transport efficacy can be significantly augmented by applying electric pulses to plasma membrane, which opens transient non-selective hydrophilic nanopores as additional pathways across lipid membranes. Electroporation (EP) has been utilized to facilitate drug uptake in electrochemotherapy (ECT) and has been tested in combination with PDT. In the review, we described effects of PDT and electrophotodynamic therapy (EPDT) on carcinoma and healthy cells, studied in vitro and vivo. The comparison of different drugs has been applied to tests considering the enhancement of their cytotoxicity, selectivity, and additional effects caused by electroporation.

Keywords: Cytotoxicity; ECT; EP; EPDT; PDT; Photodynamic therapy; Photosensitizer; ROS; cancer; electrochemotherapy; electroporation

Document Type: Research Article

Publication date: 01 March 2013

More about this publication?
  • Current Drug Metabolism aims to cover all the latest and outstanding developments in drug metabolism and disposition. The journal serves as an international forum for the publication of timely reviews in drug metabolism. Current Drug Metabolism is an essential journal for academic, clinical, government and pharmaceutical scientists who wish to be kept informed and up-to-date with the latest and most important developments. The journal covers the following areas:

    In vitro systems including CYP-450; enzyme induction and inhibition; drug-drug interactions and enzyme kinetics; pharmacokinetics, toxicokinetics, species scaling and extrapolations; P-glycoprotein and transport carriers; target organ toxicity and interindividual variability; drug metabolism and disposition studies; extrahepatic metabolism; phase I and phase II metabolism; recent developments for the identification of drug metabolites and adducts.
  • Editorial Board
  • Information for Authors
  • Subscribe to this Title
  • Ingenta Connect is not responsible for the content or availability of external websites
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content